TIRZ GLP-2 — 30 mg

The name TIRZ commonly abbreviates tirzepatide. Its relevant receptor activities are GIP and GLP-1, making it a dual-incretin agonist. A label such as GLP-2 appears to refer informally to two-target activity; it must not be interpreted as identifying glucagon-like peptide-2 or a GLP-2-receptor agonist. The supplied Umbrella catalog capture did not establish an exact product under this requested name, so the identity is interpreted from the TIRZ shorthand rather than independently confirmed from that listing.

Lilly describes tirzepatide as a dual GIP/GLP-1 compound in its diabetes-development materials. In the SURMOUNT-1 obesity trial, researchers observed substantial average weight reduction over 72 weeks in adults without diabetes, alongside frequent gastrointestinal adverse events. These sources support research descriptions involving body-weight regulation and glycemic physiology. They do not support relabeling the molecule as the intestinal hormone GLP-2. For a catalog entry, retaining the requested heading while explicitly naming tirzepatide prevents confusion and preserves the difference between a commercial naming convention, molecular identity, and an experimentally defined receptor mechanism.